The recent demonstration of antinociceptive activity of NE 52-QQ57 highlights a potential avenue for exploration (Velcicky et al., 2017), as does the potential application of another GPR4 antagonist for treatment of myocardial infarction (Fukuda et al., 2016). This evidence concerns the gene GPR4 and myocardial infarction.